Antibodies to polyethylene glycol
AssigneeBristol-Myers Squibb Company
InventorsMurli Krishna, Alexander T. Kozhich, Martin J. Corbett, Zheng Lin, Steven P. Piccoli
Life of this patent
Estimating the term…
Abstract
Polyethylene glycol (PEG) is often conjugated with therapeutic proteins to enhance their PK properties. PEG may, however, be immunogenic, and the presence of PEG in food and cosmetics is believed to result in pre-existing anti-PEG antibodies in humans. Polyclonal and monoclonal antibodies reactive to PEG are provided for use in immunogenicity assay development to detect such anti-drug antibodies. Such antibodies exhibit preferential binding based on the size of PEG with molecular weight ranging from 350 daltons to 40 kD. Anti-PEG antibodies of the invention are engineered to comprise human Fc regions to enable non-bridging immunoassay formats.
Claims8
An isolated anti-polyethylene glycol (PEG) antibody comprising:
- a. a heavy chain variable domain comprising:
- i. CDRH1 (residues 31-35 of SEQ ID NO:
- 2);
- ii. CDRH2 (residues 50-68 of SEQ ID NO:
- 2);
- and
- iii. CDRH3 (residues 101-109 of SEQ ID NO:
- 2), and
- b. a light chain variable domain comprising:
- i. CDRL1 (residues 31-37 of SEQ ID NO:
- 4);
- ii. CDRL2 (residues 50-56 of SEQ ID NO:
- 4);
- and
- iii. CDRL3 (residues 89-102 of SEQ ID NO:
- 4).
An isolated anti-PEG antibody comprising:
- a. a heavy chain variable domain comprising:
- i. CDRH1 (residues 31-35 of SEQ ID NO:
- 6);
- ii. CDRH2 (residues 50-66 of SEQ ID NO:
- 6);
- and
- iii. CDRH3 (residues 99-110 of SEQ ID NO:
- 6), and
- b. a light chain variable domain comprising:
- i. CDRL1 (residues 24-34 of SEQ ID NO:
- 8);
- ii. CDRL2 (residues 50-56 of SEQ ID NO:
- 8);
- and
- iii. CDRL3 (residues 89-102 of SEQ ID NO:
- 8), or
- i. CDRL1 (residues 24-39 of SEQ ID NO:
- 10);
- ii. CDRL2 (residues 55-61 of SEQ ID NO:
- 10);
- and
- iii. CDRL3 (residues 94-102 of SEQ ID NO:
- 10).
Dependencies are inferred from the claim text.